BioMarin Pharmaceutical (NASDAQ:BMRN) Earns "Neutral" Rating from HC Wainwright

Key Points

• HC Wainwright reaffirmed a "neutral" rating on BioMarin with a $55 price target, implying roughly a 0.8% downside from the current share price.
• BioMarin beat Q1 revenue ($766.2M) and raised full-year revenue guidance to $3.825B–$3.925B, but Q1 EPS missed expectations ($0.76 vs. ~$0.94) and FY EPS guidance (4.85–5.05) is slightly below some analyst forecasts, leaving a mixed outlook.
• Despite the mixed results, analysts' consensus is a "Moderate Buy" with a consensus target of $90.91, even as some brokers trimmed price targets and insiders disclosed stock sales.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report)'s stock had its "neutral" rating reaffirmed by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $55.00 price target on the biotechnology company's stock. HC Wainwright's price target suggests a potential downside of 0.83% from the company's current price.

BMRN has been the topic of a number of other research reports. Bank of America reduced their target price on BioMarin Pharmaceutical from $97.00 to $85.00 and set a "buy" rating on the stock in a research note on Wednesday, March 11th. Stifel Nicolaus set a $68.00 price target on BioMarin Pharmaceutical in a research report on Tuesday, February 24th. Truist Financial raised BioMarin Pharmaceutical to a "strong-buy" rating in a report on Wednesday, March 25th. Oppenheimer reduced their price objective on BioMarin Pharmaceutical from $98.00 to $95.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 24th. Finally, Piper Sandler decreased their price objective on BioMarin Pharmaceutical from $122.00 to $84.00 and set an "overweight" rating on the stock in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $90.91.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $55.46 on Tuesday. The company has a current ratio of 5.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.10. The company's 50-day moving average price is $56.93 and its 200 day moving average price is $56.32. BioMarin Pharmaceutical has a 52 week low of $50.76 and a 52 week high of $66.28. The stock has a market cap of $10.72 billion, a price-to-earnings ratio of 31.16, a PEG ratio of 0.54 and a beta of 0.23.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 16,486 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the transaction, the executive vice president directly owned 79,953 shares in the company, valued at approximately $4,833,958.38. This represents a 17.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregory R. Friberg sold 6,326 shares of the firm's stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares in the company, valued at approximately $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.85% of the company's stock.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC grew its stake in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after buying an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its holdings in BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company's stock valued at $2,554,000 after acquiring an additional 183 shares during the last quarter. Nisa Investment Advisors LLC grew its position in BioMarin Pharmaceutical by 7.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company's stock valued at $163,000 after acquiring an additional 195 shares during the period. Grandfield & Dodd LLC grew its position in BioMarin Pharmaceutical by 1.2% during the third quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company's stock valued at $1,027,000 after acquiring an additional 217 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in BioMarin Pharmaceutical by 3.4% during the third quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company's stock worth $387,000 after acquiring an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q1 revenue beat — BioMarin reported $766.2M in revenue, above consensus, driven by portfolio contributions and year-over-year growth; management highlighted revenue expansion in the release. BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Company raised full-year revenue guidance to $3.825B–$3.925B (accelerated growth ~20% Y/Y at midpoint), signaling stronger sales outlook for FY2026. BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Portfolio additions (GALAFOLD and POMBILITI + OPFOLDA) were cited as drivers behind the revenue upgrade and should support continued top-line growth. BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Brokerage sentiment remains constructive — the company has an average rating of "Moderate Buy" from analysts, which can support investor confidence. BioMarin Pharmaceutical Inc. NASDAQ: BMRN Receives Average Rating of "Moderate Buy" from Brokerages
• Neutral Sentiment: Management held an earnings call and posted the slide deck and transcript; these materials provide detail on product dynamics and cost assumptions but didn’t change the headline mix of beat/miss. BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed consensus: reported $0.76 vs. estimates around $0.94, and EPS declined year-over-year — a clear near-term profitability weakness that pressured some investor expectations. BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates
• Negative Sentiment: FY EPS guidance (4.85–5.05) sits slightly below some analyst expectations at the midpoint, limiting upside to EPS-focused investors despite the higher revenue guide. Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.